Formation Bio

Executive Summary

Formation Bio is an AI-native pharmaceutical company founded in 2020 and headquartered in San Francisco. By leveraging a proprietary technology platform, the company aims to accelerate drug development by acquiring and advancing clinical-stage assets. Its lead candidate, ASN008, is a topical therapy for atopic dermatitis and pruritus, having completed a Phase 2 trial in December 2023. The company's AI-driven approach promises to streamline clinical trials and reduce development timelines, positioning it to bring treatments to market faster. With a focus on efficiency and a data-driven pipeline, Formation Bio represents a new wave of tech-enabled biopharma.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 3 Trials for ASN00870% success
• TBDAnnouncement of New Asset Acquisition50% success
• TBDPartnership or Licensing Deal for AI Platform40% success